109904-27-0

Basic information

• Product Name: 2-Oxo Clopidogrel Hydrochloride (Mixture of diastereomers)
• Synonyms: a-(2-Chlorophenyl)-2,6,7,7a-tetrahydro-2-oxo-thieno[3,2-c]pyridine-5(4H)-acetic Acid Methyl Ester Hydrochloride;2-OXO CLOPIDOGREL HYDROCHLORIDE;2-Oxo-Clopidogrel-d4 (Mixture of DiastereoMers);2-Oxo Clopidogrel (Mixture of IsoMers);methyl 2-(2-chlorophenyl)-2-(2-oxo-7,7a-dihydrothieno[3,2-c]pyridin-5(2H,4H,6H)-yl)acetate;Methyl (2-Chlorophenyl)(2-Oxo-2,6,7,7alpha-Tetrahydrothieno[3,2-c]Pyridin-5(4H)-Yl)Acetate;2-Oxo Clopidogrel Hydrochloride (Mixture of diastereomers);a-(2-Chlorophenyl)-2,6,7,7a-tetrahydro-2-oxo-thieno[3,2-c]pyridine-5(4H)-acetic Acid Methyl Ester Hydrochlorid
• CAS NO: 109904-27-0
• Molecular Formula: C16H17Cl2NO3S
• Molecular Weight: 374.28208
• Product Categories: Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Heterocycles;Various Metabolites and Impurities
• Mol File: 109904-27-0.mol
• Article Data: 19

Chemical Properties

• Melting Point: 133-1350C
• Boiling Point: 488.1±45.0 °C(Predicted)
• Appearance: /
• Density: 1.39±0.1 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 3.41±0.20(Predicted)
• CAS DataBase Reference: 2-Oxo Clopidogrel Hydrochloride (Mixture of diastereomers)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Oxo Clopidogrel Hydrochloride (Mixture of diastereomers)(109904-27-0)
• EPA Substance Registry System: 2-Oxo Clopidogrel Hydrochloride (Mixture of diastereomers)(109904-27-0)

Safety Data

• Hazardous Substances Data: 109904-27-0(Hazardous Substances Data)

Usage

Description

2-Oxo Clopidogrel Hydrochloride (Mixture of diastereomers) is a beige solid that serves as an essential intermediate metabolite in the formation of the active metabolite of Clopidogrel, a widely used antiplatelet drug.

Uses

Used in Pharmaceutical Industry:
2-Oxo Clopidogrel Hydrochloride (Mixture of diastereomers) is used as an intermediate metabolite for the synthesis of the active metabolite of Clopidogrel, which is an antiplatelet drug. This application is crucial in the treatment and prevention of various cardiovascular conditions, such as myocardial infarction, stroke, and peripheral arterial disease, by inhibiting platelet aggregation and reducing the risk of blood clot formation.

Upstream product

• 90055-47-3 methyl 2-chloro-2-(2-chlorophenyl)acetate 
• 115473-15-9 5,6,7,7a-tetrahydro-thieno[3,2-c]pyridin-2(4H)-one hydrochloride 
• 32345-60-1 methyl (S)-2-hydroxy-2-(2-chlorophenyl)acetate 
• 156276-21-0 rac-methyl 2-chloromandelate 
• 10421-85-9 (R)-2-chloromandelic acid 
• 109904-37-2 5,6,7,7a-tetrahydrothieno[3,2-c]pyridine-2(4H)-one monohydrochloride 
• 32345-59-8 methyl (R)-2-chloromandelate 
• 113665-84-2 (S)-(+)-clopidogrel 
• 85259-19-4 methyl 2-bromo-2-(2-chlorophenyl)acetate 

Downstream Products

• 1147350-77-3 cis-5-thiol metabolite 
• 767612-34-0 R-361015 
• 1351983-68-0 C₁₆H₁₈ClNO₄S 
• 1122047-98-6 C₂₅H₂₆ClNO₆S 
• 1416696-48-4 methyl (7aR,2'S)-2-(2-chlorophenyl)-2-(2,4,5,6,7,7a-hexahydrothieno[3,2-c]-5-pyridin-2-one)acetate 
• 1416696-44-0 methyl (7aS,2'S)-2-(2-chlorophenyl)-2-(2,4,5,6,7,7a-hexahydrothieno[3,2-c]-5-pyridin-2-one)acetate 
• 1416696-58-6 methyl (7aS,2'S)-2-(2-chlorophenyl)-2-(2,4,5,6,7,7a-hexahydrothieno[3,2-c]-5-pyridin-2-one)acetate hydrogen sulfate 
• 767612-34-0 (Z)-2-(1-(1-(2-chlorophenyl)-2-methoxy-2-carbonylethyl)-4-mercaptopiperidinyl-3-enyl)acetic acid 
• 767612-34-0 C₁₆H₁₈ClNO₄S 

Relevant articles and documents

In Vitro Assessment of Potential for CYP-Inhibition-Based Drug–Drug Interaction Between Vonoprazan and Clopidogrel

Background and Objectives: It was recently proposed that CYP-mediated drug–drug interactions (DDIs) of vonoprazan with clopidogrel and prasugrel can attenuate the antiplatelet actions of the latter two drugs. Clopidogrel is metabolized to the pharmacologically active metabolite H4 and its isomers by multiple CYPs, including CYP2C19 and CYP3A4. Therefore, to investigate the possibility of CYP-based DDIs, in vitro metabolic inhibition studies using CYP probe substrates or radiolabeled clopidogrel and human liver microsomes (HLMs) were conducted in this work. Methods: Reversible inhibition studies focusing on the effects of vonoprazan on CYP marker activities and the formation of the [14C]clopidogrel metabolite H4 were conducted with and without pre-incubation using HLMs. Time-dependent inhibition (TDI) kinetics were also measured. Results: It was found that vonoprazan is not a significant direct inhibitor of any CYP isoforms (IC50 ≥ 16?μM), but shows the potential for TDI of CYP2B6, CYP2C19, and CYP3A4/5. This TDI was weaker than the inhibition induced by the corresponding reference inhibitors ticlopidine, esomeprazole, and verapamil, based on the measured potencies (kinact/KI ratio and the R2 value). In a more direct in vitro experiment, vonoprazan levels of up to 10?μM (a 100-fold higher concentration than the plasma Cmax of 75.9?nM after taking 20?mg once daily for 7?days) did not suppress the formation of the active metabolite H4 or other oxidative metabolites of [14C]clopidogrel in a reversible or time-dependent manner. Additionally, an assessment of clinical trials and post-marketing data suggested no evidence of a DDI between vonoprazan and clopidogrel. Conclusions: The body of evidence shows that the pharmacodynamic DDI reported between vonoprazan and clopidogrel is unlikely to be caused by the inhibition of CYP2B6, CYP2C19, or CYP3A4/5 by vonoprazan.

To the editor

-

THIENOPYRIDINE DERIVATIVES CONTAINING UNSATURATED ALIPHATIC OLEFINIC BOND, PREPARATION METHOD AND USE THEREOF

The present invention provides a compound having a structure of formula (I), a preparation method and use thereof, and a pharmaceutical composition containing the compound, wherein R is methyl, ethyl, propyl, vinyl or propenyl. The present invention also